Dr. Eric Topol is the editor in chief of Medscape. He is a Cardiologist and a Geneticist with an interest in how technology affects health. Artificial Intelligence (AI) is the ability of a digital computer or computer-controlled robot to perform tasks commonly associated with intelligent beings. AI has become the buzz word in medicine, computer science, and engineering. Machine learning, in artificial intelligence the discipline concerned with the implementation of computer software that can learn autonomously. In his latest book, ‘Deep Medicine’ Dr. Topol describes how medicine is broken today and how artificial intelligence can help make healthcare human again. Listen to this 5-minute video clip by Dr.
It can be difficult to approach a colleague if you have concerns about their wellbeing because of a change in their behaviour. Abi Rimmer asks experts how best to handle this situation. Remember a) small gestures make a BIG difference b) Take your doctor hat off c) Don’t be embarrassed to ask Small gestures make a big difference Lucy Warner, chief executive of the NHS Practitioner Health Programme, says, “If you’ve noticed a change, then this situation has probably been around for some time and may already have become a fairly serious problem. Doctors are very good at focusing
In an era that that ‘evidence-based medicine’ is facing challenges from many fronts, the benefits of blood pressure control have been shown to decrease morbidity and mortality and increase lifespan. The evidence is strong and there is no disagreement among clinicians and researchers. However, there is considerable uncertainty and debate as to how much reduction is needed in systolic blood pressure among the leading guidelines that look at the same evidence. The JNC 2018, AHA/ACC and now NICE guidelines vary with the recommendations. The page below gives the summary of guidelines available from JNC 8 (2014), ACC/AHA (2107) and ESC/ESH
In the new guidelines, statin treatment targets are back for both primary and secondary prevention. Patients whose 10-year risk of ASCVD is 20% or more should try to reduce LDL-C levels by at least 50%, the same goal as for people with clinical ASCVD. Those with more intermediate risk should aim for at least a 30% decrease. The new update was met with considerably less controversy than the last incarnation, which deemphasized LDL-C treatment targets and introduced the AHA/ACC ASCVD risk calculator. The updated guidelines and a companion AHA/ACC special report on risk assessment tools acknowledge that the calculator estimates risk for an average